Eastman Chemicalの空売り状況は、投資家がEastman Chemicalの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Eastman Chemical (NYSE:EMN) 株価情報, 空売り情報

Eastman Chemical

Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.

Eastman Chemical Co

Euro Manganese Inc

E-MONEE.COM INC by E-Monee.com, Inc.

Elementis PLC

PIMCO Enhanced Short Maturity Active ESG Exchange-Traded Fund

<p>In the latest quarter, 10 analysts provided ratings for Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $111.0, a high estimate of $125.00, and a low estimate of $102.00. Highlighting a 1.77% decrease, the current average has fallen from the previous average price target of $113.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738357238_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of Eastman Chemical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$123.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$102.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$117.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$110.00</td>
<td>$118.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eastman Chemical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eastman Chemical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Eastman Chemical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Eastman Chemical's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EMN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Eastman Chemical analyst ratings.</strong></a></p>
<h2>All You Need to Know About Eastman Chemical</h2>
<p>Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.</p>
<h3>Eastman Chemical's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Eastman Chemical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>8.69%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Eastman Chemical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.31%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Eastman Chemical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>3.19%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Eastman Chemical's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.2%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Eastman Chemical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.89</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Analyst Expectations For Eastman Chemical's Future

<p>UBS  analyst Joshua Spector   maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Buy and lowers the price target from $124 to $123.</p>


News

Price Target

UBS Maintains Buy on Eastman Chemical, Lowers Price Target to $123

WIIM

Eastman Chemical shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results.

<p>U.S. stocks were higher, with the Nasdaq Composite gaining more than 1% on Friday.</p>
<p>Shares of <strong>Charter Communications, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) rose during Friday's session after the company reported <a href="https://in.benzinga.com/25/01/43390140/charter-q4-earnings-beats-estimates-mobile-growth-surges-with-529k-new-lines-despite-broadband-subscriber-losses">better-than-expected fourth-quarter financial results.</a></p>
<p>Charter Communications reported fiscal fourth-quarter 2024 revenue growth of 1.6% year-on-year to $13.93 billion, beating the analyst consensus estimate of $13.88 billion. EPS of $10.10 beat the analyst consensus estimate of $9.22.</p>
<p>Charter Communications shares jumped 5.4% to $354.63 on Friday.</p>
<p>Here are some other big stocks recording gains in today's session.</p>
<ul>
<li><strong>Viavi Solutions Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) shares jumped 26% to $12.58 after the company reported better-than-expected second-quarter financial results.</li>
<li><strong>Diginex Limited</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) gained 22% to $42.60.</li>
<li><strong>Cipher Mining Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) shares rose 21.8% to $5.73 after the company announced a $50 million investment from Softbank.</li>
<li><strong>Atlassian Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) gained 17.7% to $314.07 as the company reported better-than-expected financial results for the fiscal second quarter after the market close on Thursday.</li>
<li><strong>SkyWest, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>) gained 15.3% to $134.63 following strong quarterly earnings.</li>
<li><strong>Celestica Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) rose 15.3% to $131.62. The company recently posted better-than-expected fourth-quarter financial results.</li>
<li><strong>AST SpaceMobile, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) rose 14.6% to $20.87 after the company announced the FCC granted the company Special Temporary Authority, authorizing testing service in the U.S.</li>
<li><strong>Credo Technology Group Holding Ltd</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) surged 13% to $72.93.</li>
<li><strong>RBC Bearings Incorporated</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) rose 12.1% to $360.84 following upbeat earnings.</li>
<li><strong>Redwire Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) gained 10.1% to $25.06.</li>
<li><strong>JetBlue Airways Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) rose 9% to $6.89.</li>
<li><strong>Mobileye Global Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) gained 8.5% to $17.69.</li>
<li>E<strong>astman Chemical Company </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) surged 7.7% to $99.84 after the company reported better-than-expected quarterly adjusted EPS results.</li>
<li><strong>AbbVie Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) gained 7.4% to $188.60. The company reported fourth-quarter adjusted earnings per share of $2.16, beating the street view of $2.11.</li>
<li><strong>Vertex Pharmaceuticals Incorporated</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) rose 5.8% to $463.83 after the company announced it secured FDA approval for JOURNAVX. Also, the company announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access CASGEVY.</li>
<li><strong>Baker Hughes Company</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) gained 4.6% to $46.68 following upbeat earnings.</li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/01/43335398/wall-streets-most-accurate-analysts-spotlight-on-3-risk-off-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Risk Off Stocks Delivering High-Dividend Yields</a></strong></li>
</ul>


Intraday Update

Markets

Movers

Trading Ideas

ABBV

ASTS

CHTR

CIFR

CRDO

DGNX

JBLU

MBLY

SKYW

TEAM

VIAV

VRTX

Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical, AbbVie And Other Big Stocks Moving Higher On Friday

<p>The Q4 earnings report for <strong>Eastman Chemical</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) was released on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Eastman Chemical beat estimated earnings by 19.0%, reporting an EPS of $1.87 versus an estimate of $1.57.</p>
<p>Revenue was up $38.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat on EPS by $0.12 which was followed by a 4.0% drop in the share price the next day.</p>
<p>Here's a look at Eastman Chemical's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.14</td>
<td>2.01</td>
<td>1.43</td>
<td>1.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.15</td>
<td>1.61</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.38B</td>
<td>2.36B</td>
<td>2.29B</td>
<td>2.21B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.46B</td>
<td>2.36B</td>
<td>2.31B</td>
<td>2.21B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Eastman Chemical management provided guidance for FY 2025, expecting earnings between $8.0 and $8.75 per share.</p>
<p>To track all earnings releases for Eastman Chemical <a href="https://www.benzinga.com/quote/EMN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

Insights into Eastman Chemical Q4 Earnings

<p><strong>Eastman Chemical</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) reported its Q4 earnings results on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Eastman Chemical beat estimated earnings by 19.0%, reporting an EPS of $1.87 versus an estimate of $1.57.</p>
<p>Revenue was up $38.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat on EPS by $0.12 which was followed by a 4.0% drop in the share price the next day.</p>
<p>Here's a look at Eastman Chemical's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.14</td>
<td>2.01</td>
<td>1.43</td>
<td>1.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.15</td>
<td>1.61</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.38B</td>
<td>2.36B</td>
<td>2.29B</td>
<td>2.21B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.46B</td>
<td>2.36B</td>
<td>2.31B</td>
<td>2.21B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Eastman Chemical management provided guidance for FY 2025, expecting earnings between $8.0 and $8.75 per share.</p>
<p>To track all earnings releases for Eastman Chemical <a href="https://www.benzinga.com/quote/EMN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Eastman Chemical Q4

<p><strong>Eastman Chemical</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) released its Q4 earnings on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Eastman Chemical beat estimated earnings by 19.0%, reporting an EPS of $1.87 versus an estimate of $1.57.</p>
<p>Revenue was up $38.00 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>Last quarter the company beat on EPS by $0.12 which was followed by a 4.0% drop in the share price the next day.</p>
<p>Here's a look at Eastman Chemical's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.14</td>
<td>2.01</td>
<td>1.43</td>
<td>1.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.15</td>
<td>1.61</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.38B</td>
<td>2.36B</td>
<td>2.29B</td>
<td>2.21B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.46B</td>
<td>2.36B</td>
<td>2.31B</td>
<td>2.21B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Eastman Chemical management provided guidance for FY 2025, expecting earnings between $8.0 and $8.75 per share.</p>
<p>To track all earnings releases for Eastman Chemical <a href="https://www.benzinga.com/quote/EMN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: Eastman Chemical Q4

<p><strong>Eastman Chemical</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) reported its Q4 earnings results on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Eastman Chemical beat estimated earnings by 19.0%, reporting an EPS of $1.87 versus an estimate of $1.57.</p>
<p>Revenue was up $38.00 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.12, leading to a 4.0% drop share price change the next day.</p>
<p>Here's a look at Eastman Chemical's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.14</td>
<td>2.01</td>
<td>1.43</td>
<td>1.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.15</td>
<td>1.61</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.38B</td>
<td>2.36B</td>
<td>2.29B</td>
<td>2.21B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.46B</td>
<td>2.36B</td>
<td>2.31B</td>
<td>2.21B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Eastman Chemical management provided guidance for FY 2025, expecting earnings between $8.0 and $8.75 per share.</p>
<p>To track all earnings releases for Eastman Chemical <a href="https://www.benzinga.com/quote/EMN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Eastman Chemical Q4 Earnings Assessment

<p><strong>Eastman Chemical</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) reported its Q4 earnings results on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Eastman Chemical beat estimated earnings by 19.0%, reporting an EPS of $1.87 versus an estimate of $1.57.</p>
<p>Revenue was up $38.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company beat on EPS by $0.12 in the previous quarter, leading to a 4.0% drop share price change the next day.</p>
<p>Here's a look at Eastman Chemical's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.14</td>
<td>2.01</td>
<td>1.43</td>
<td>1.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.15</td>
<td>1.61</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.38B</td>
<td>2.36B</td>
<td>2.29B</td>
<td>2.21B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.46B</td>
<td>2.36B</td>
<td>2.31B</td>
<td>2.21B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Eastman Chemical management provided guidance for FY 2025, expecting earnings between $8.0 and $8.75 per share.</p>
<p>To track all earnings releases for Eastman Chemical <a href="https://www.benzinga.com/quote/EMN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: Eastman Chemical Q4 Earnings

<p><strong>Eastman Chemical</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) just disclosed its Q4 earnings on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Eastman Chemical beat estimated earnings by 19.0%, reporting an EPS of $1.87 versus an estimate of $1.57.</p>
<p>Revenue was up $38.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.12 in the previous quarter, leading to a 4.0% drop share price change the next day.</p>
<p>Here's a look at Eastman Chemical's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.14</td>
<td>2.01</td>
<td>1.43</td>
<td>1.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.15</td>
<td>1.61</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.38B</td>
<td>2.36B</td>
<td>2.29B</td>
<td>2.21B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.46B</td>
<td>2.36B</td>
<td>2.31B</td>
<td>2.21B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Eastman Chemical management provided guidance for FY 2025, expecting earnings between $8.0 and $8.75 per share.</p>
<p>To track all earnings releases for Eastman Chemical <a href="https://www.benzinga.com/quote/EMN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Eastman Chemical Earnings Analysis: Q4 Recap

<p><strong>2025 Outlook</strong></p>
<p>Commenting on the outlook for full-year 2025, Costa said: "As we begin 2025, the global economic and geopolitical environment remains highly uncertain. Despite this uncertainty, we are confident in our ability to generate growth across our portfolio as we build upon a strong year in 2024. First, we expect modest volume growth in our specialty businesses, and we will continue to leverage our innovation-driven growth model to deliver growth above underlying challenged market trends. Across our consumer discretionary end markets, we are not projecting any underlying demand improvement in 2025. Across our more stable markets, we are projecting modest demand growth. A key driver of our innovative growth will be our circular platform as we remain on track with our 2025 commitments of $75 million-$100 million EBITDA growth shared recently at our Circular Deep Dive event. And finally, we will reduce structural costs to more than offset inflation while continuing to invest in growth and capabilities for long-term value creation. Partially offsetting these factors include headwinds related to higher energy costs, a stronger U.S. dollar, and customer inventory management in the Fibers business. Taking this together, we expect 2025 EPS to be between $8.00-$8.75 and for 2025 cash from operations to be approximately $1.3 billion."</p>
<p>The full-year 2025 projected adjusted diluted EPS and Earnings Before Interest, Taxes, Depreciation, and Amortization ("EBITDA") exclude any non-core, unusual, or nonrecurring items. Our financial results forecasts do not include non-core items (such as mark-to-market pension and other postretirement benefit gain or loss, and asset impairments and restructuring charges) or any unusual or non-recurring items because we are unable to predict with reasonable certainty the financial impact of such items. These items are uncertain and depend on various factors, and we are unable to reconcile projected adjusted diluted EPS and EBITDA excluding non-core and any unusual or non-recurring items to reported GAAP diluted EPS or net earnings without unreasonable efforts.</p>


Guidance

Eastman Sees Uncertain 2025 Outlook: Projects Modest Volume Growth in Specialty Businesses, Leveraging Innovation Model, Aiming for $75M-$100M EBITDA Boost; Focus on Circular Platform, Cost Reductions To Counter Inflation And Energy Costs; 2025 EPS Estimated At $8.00-$8.75 Vs $8.52 Est.

<p>Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) reported quarterly earnings of $1.87 per share which beat the analyst consensus estimate of $1.57 by 19.11 percent. This is a 42.75 percent increase over earnings of $1.31 per share from the same period last year.  The company reported quarterly sales of $2.25 billion which missed the analyst consensus estimate of $2.27 billion by 1.24 percent.  This is a 1.72 percent increase over sales of $2.21 billion the same period last year.</p>


Earnings Beats

Earnings Misses

Eastman Chemical Q4 Adj $1.87 Beats $1.57 Estimate, Sales $2.25B Miss $2.27B Estimate

AAPL

ABCB

ALGM

APPF

Adtalem Global Education Inc. Common Stock

ATGE

BAFN

BBVA

BHLB

BOOT

CACC

CHKP

CIVB

CMCSA

CNOB

COUR

CSWI

CVCO

DECK

FBIZ

FCFS

FFWM

FINW

FISI

FLWS

FRME

GSIT

INTC

KLAC

KRNY

LPLA

MBUU

NTCT

ONEW

PFSI

REAL

SCSC

SHEL

SILC

SIRI

STBA

STEL

Earnings Scheduled For January 30, 2025

<p>The chemical industry could be in for a turbulent 2025 spurred by increased demand, cost inflation and President-elect<strong> </strong><a href="https://www.benzinga.com/markets/commodities/24/11/42235640/trumps-energy-policies-poised-to-reshape-oil-gas-market-winners-and-losers-revealed"><strong>Donald Trump</strong>&#8216;s PFAS policies</a>.</p>
<p><strong>The Chemicals Analyst:</strong> Bank of America analyst Steve Byrne released a note covering the chemicals industry on Tuesday, upgrading and downgrading several companies:</p>
<ul>
<li><strong>Archer-Daniels-Midland Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) from Neutral to Underperform, lowering its price target from $63 to $54.</li>
<li><strong>Celanese Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Underperform to Buy, lowering its price target from $95 to $88.</li>
<li><strong>Eastman Chemical Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) from Neutral to Buy, lowering its price target from $115 to $109.</li>
<li><strong>Element Solutions Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) from Buy to Neutral, lowering its price target from $32 to $28.</li>
<li><strong>FMC Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) from Underperform to Neutral, lowering its price target from $63 to $61.</li>
<li><strong>Olin Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) from Neutral to Buy, lowering its price target from $48 to $40.</li>
<li><strong>Origin Materials Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGN#NASDAQ">ORGN</a>) from Buy to Underperform, lowering its price target from $2.50 to $1.50.</li>
</ul>
<p><strong>Main Takeaways:</strong> Agriculture stocks faced a decline in the waning months of 2024, amid market concerns over potential trade policies under President-elect Trump and the impact of rising interest rates linked to the federal deficit. Byrne believes the market has already re-priced higher risk.</p>
<p>The analyst believes chemicals will see increased demand with a caveat.</p>
<p>&#8220;We expect end-market demand to grow this year, although we&#8217;ve pared back expectations, given incremental headwinds from tariff concerns, a strong USD, and higher interest rate expectations, among others,&#8221; Byrne said. &#8220;Still, the U.S. Manufacturing PMI has been surprisingly weak and the risk-reward is skewed positively in our view.&#8221;</p>
<p>Meanwhile, the analyst foresees a return of inflationary pressures on input costs, squeezing margins.</p>
<p>Byrne says Trump&#8217;s election win and a possible &#8220;trade war&#8221; could slow GDP growth and hurt chemical companies&#8217; bottom lines. He notes deregulation and lower corporate taxes as a positive. The analyst suggests that Trump&#8217;s weakening of the EPA could pause certain regulatory initiatives, potentially increasing litigation risks for PFAS manufacturers.</p>
<p><strong>Company Takeaways:</strong> Byrne cited declining profitability and increased macroeconomic risk for his Archer-Daniels-Midland downgrade.</p>
<p>The analyst upgraded Celanese&#8217;s stock based on an expected demand recovery, an attractive valuation and potential benefits from shareholder activism.</p>
<p>Eastman Chemical took a severe hit in 2024&#8217;s fourth quarter. Byrne says the market&#8217;s sell-off was &#8220;overdone&#8221; and is optimistic for future revenue and earnings growth.</p>
<p>Byrne downgraded Element Solutions and said there is better opportunity elsewhere. He noted possible currency headwinds.</p>
<p>FMC could face a tough recovery from its struggles in 2024, but Byrne is optimistic that the company&#8217;s EBITDA can rebound. The analyst says market multiples are &#8220;appropriately reflecting risks.&#8221;</p>
<p>Byrne says Olin&#8217;s valuation is &#8220;highly attractive&#8221; due to its high free cash flow yield. The analyst also said the company is insulated from Trump administration risks.</p>
<p>The analyst&#8217;s downgrade of Origin Materials is linked to doubts that the company will be able to license its technology and possible headwinds for sustainable products.</p>
<p><strong>Price Action:</strong> Several of the companies showed sharp movement following the analyst&#8217;s note:</p>
<ul>
<li>Archer-Daniels-Midland traded at $51.18, down 1.8%.</li>
<li>Celanese Corporation traded at $71.97, up 6.81%.</li>
<li>Eastman Chemical traded at $91.77, up 2.99%.</li>
<li>FMC Corp traded at $53.16, up 2.17%.</li>
<li>Olin Corp traded at $33.10, up 4.38%.</li>
<li>Origin Materials traded at $1, down 9.9%.</li>
</ul>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42974739/wall-street-rebounds-as-producer-inflation-misses-estimates-tesla-gains-chinese-stocks-rally">Wall Street Rebounds As Producer Inflation Misses Estimates, Tesla Gains, Chinese Stocks Rally</a></strong></li>
</ul>
<p><em>Photo: dongfang/Shutterstock.com</em></p>


Analyst Color

Government

Regulations

Upgrades

Downgrades

Economics

ORGN

Increased Demand, Trump Administration Risks: Analyst Picks Celanese As Chemical Winner, ADM As Loser For 2025

<p>B of A Securities  analyst Steve Byrne   upgrades Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) from Neutral to Buy and lowers the price target from $115 to $109.</p>


B of A Securities Upgrades Eastman Chemical to Buy, Lowers Price Target to $109

Eastman Chemical Says Effective Feb 1, Off-List Price Increase In North America & Latin America For Eastman DB Solvent, Excluding EastaPure: $0.05/lb, For Eastman DTB Solvent: $0.05/lb

<p>Piper Sandler  analyst Charles Neivert   maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Neutral and lowers the price target from $105 to $102.</p>


Piper Sandler Maintains Neutral on Eastman Chemical, Lowers Price Target to $102

<p>11 analysts have expressed a variety of opinions on Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $112.09, a high estimate of $125.00, and a low estimate of $104.00. This upward trend is apparent, with the current average reflecting a 1.73% increase from the previous average price target of $110.18.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734548418_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Eastman Chemical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$117.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$110.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$119.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$118.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$107.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eastman Chemical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Eastman Chemical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Eastman Chemical's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Eastman Chemical's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EMN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Eastman Chemical analyst ratings.</strong></a></p>
<h2>Get to Know Eastman Chemical Better</h2>
<p>Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.</p>
<h3>Understanding the Numbers: Eastman Chemical's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Eastman Chemical showcased positive performance, achieving a revenue growth rate of <strong>8.69%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Eastman Chemical's net margin is impressive, surpassing industry averages. With a net margin of <strong>7.31%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.19%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Eastman Chemical's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.2%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Eastman Chemical's debt-to-equity ratio is below the industry average. With a ratio of <b>0.89</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Eastman Chemical Stands With Analysts

<p>Citigroup  analyst Patrick Cunningham   downgrades Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) from Buy to Neutral and lowers the price target from $118 to $104.</p>


Citigroup Downgrades Eastman Chemical to Neutral, Lowers Price Target to $104

Reports Q4 revenue $2.25B, consensus $2.27B. "The fourth quarter capped off a tremendous year for Eastman, with adjusted earnings per share growing...

Eastman Chemical reports Q4 adjusted EPS $1.87, consensus $1.57

Eastman Chemical Non-GAAP EPS of $1.87 beats by $0.30, revenue of $2.25B misses by $20M

In a report released yesterday, John Roberts CFA from Mizuho Securities maintained a Hold rating on Eastman Chemical (EMN – Research Report), with ...

Eastman Chemical (EMN) Gets a Hold from Mizuho Securities

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – Atlassian (TEAM)&nbsp;up 19.3...

Closing Bell Movers: Atlassian up 19%, Apple gains 3% after results

Barclays analyst Michael Leithead maintained a Hold rating on Eastman Chemical (EMN – Research Report) today and set a price target of $111.00. The...

Barclays Sticks to Their Hold Rating for Eastman Chemical (EMN)

Eastman Chemical (EMN – Research Report), the Basic Materials sector company, was revisited by a Wall Street analyst yesterday. Analyst Vincent And...

Eastman Chemical's Strong Q4 Performance and Strategic Outlook Earns Buy Rating

Eastman Chemical Company 2024 Q4 - Results - Earnings Call Presentation

Notable gainers among liquid option names this morning include AbbVie (ABBV) $189.62 +13.97, Eastman Chemical (EMN) $99.51 +6.84, Vertex (VRTX) $46...

Early notable gainers among liquid option names on January 31st

Eastman Chemical projects $50M-$75M growth in circular economy platform for 2025

Eastman Chemical Company (EMN) Q4 2024 Earnings Conference Call Transcript

AESI

Press Releases

Eastman Names Iké Adeyemi as Chief Legal Officer

Eastman CFO Willie McLain to address the Morgan Stanley 12th Annual Laguna Conference

Eastman Schedules Third-Quarter 2024 Financial Results News Release and SEC Form 8-K Filing, Teleconference and Webcast, and Release of Additional Information

Eastman Announces Third-Quarter 2024 Financial Results

Notice of Public Webcast for Eastman Circular Economy Deep Dive, November 21, 2024

Eastman Highlights Circular Economy Growth and Innovation at Circular Economy Deep Dive Event

Eastman Increases Dividend for 15th Consecutive Year

Eastman Earns Equality 100 Award in Human Rights Campaign Foundation's 2025 Corporate Equality Index

Eastman Schedules Fourth-Quarter and Full-Year 2024 Financial Results News Release and SEC Form 8-K Filing, Teleconference and Webcast, and Release of Additional Information

Comments

Eastman Chemical

空売り

Eastman Chemical (NYSE:EMN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル